VICTOZA 2-PAK (liraglutide)


Drug overview for VICTOZA 2-PAK (liraglutide):

Generic name: LIRAGLUTIDE (LIR-a-GLOO-tide)
Drug class: Antihyperglycemic, Incretin Mimetic Agent
Therapeutic class: Endocrine

Liraglutide, a synthetic, long-acting human glucagon-like peptide-1 (GLP-1) receptor agonist (incretin mimetic), is an antidiabetic agent and antiobesity drug.

Liraglutide (Victoza(R)) is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus andalso is used to reduce the risk of major adverse cardiovascular events (i.e., cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke) in patients with type 2 diabetes mellitus and established cardiovascular disease. Liraglutide in fixed combination with insulin degludec (insulin degludec/liraglutide;Xultophy(R)) is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Liraglutide (Saxenda(R)) is used for chronic weight management.
DRUG IMAGES
  • VICTOZA 2-PAK 18 MG/3 ML PEN
    VICTOZA 2-PAK 18 MG/3 ML PEN
The following indications for VICTOZA 2-PAK (liraglutide) have been approved by the FDA:

Indications:
Type 2 diabetes mellitus


Professional Synonyms:
Adult onset diabetes mellitus
Adult onset diabetes
Adult onset DM
Diabetes mellitus type 2
Diabetes mellitus type II
Ketosis-resistant diabetes mellitus
Ketosis-resistant DM
Maturity onset diabetes mellitus
Maturity onset diabetes
Non-insulin dependent diabetes mellitus
Non-insulin-dependent diabetes mellitus
Type II diabetes mellitus